TSX Penny Stocks To Watch In May 2025

In This Article:

With Canada's election now behind it, one source of uncertainty has been removed, allowing policymakers to focus on trade and the economy. As the Canadian market navigates these changes, investors may find opportunities in smaller or newer companies. Penny stocks, despite their somewhat outdated name, continue to offer potential value for those seeking growth opportunities with solid financial foundations.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Westbridge Renewable Energy (TSXV:WEB)

CA$0.74

CA$74.85M

★★★★★★

NTG Clarity Networks (TSXV:NCI)

CA$1.73

CA$73.2M

★★★★★★

Silvercorp Metals (TSX:SVM)

CA$4.83

CA$1.05B

★★★★★☆

Orezone Gold (TSX:ORE)

CA$1.10

CA$576.02M

★★★★★☆

Amerigo Resources (TSX:ARG)

CA$1.71

CA$280.6M

★★★★★☆

PetroTal (TSX:TAL)

CA$0.55

CA$503.51M

★★★★★☆

Pulse Seismic (TSX:PSD)

CA$2.53

CA$128.51M

★★★★★★

McCoy Global (TSX:MCB)

CA$3.15

CA$84.74M

★★★★★★

Findev (TSXV:FDI)

CA$0.49

CA$14.04M

★★★★★★

Enterprise Group (TSX:E)

CA$1.50

CA$116.3M

★★★★★☆

Click here to see the full list of 928 stocks from our TSX Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Microbix Biosystems

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Microbix Biosystems Inc. is a life science company that develops and commercializes proprietary biological and technological solutions for human health and wellbeing across North America, Europe, and internationally, with a market cap of CA$54.92 million.

Operations: The company's revenue is primarily derived from product sales amounting to CA$23.00 million, supplemented by licensing fees and royalties totaling CA$0.03 million.

Market Cap: CA$54.92M

Microbix Biosystems Inc. has demonstrated financial resilience with short-term assets of CA$25.7 million surpassing both its short and long-term liabilities, while maintaining a cash position that exceeds its total debt. Despite a decline in net profit margins from 16.6% to 8.3%, the company remains profitable with high-quality earnings and well-covered interest payments by EBIT at 9.9 times coverage. Recent developments include an MOU with the Australian Centre for the Prevention of Cervical Cancer to supply quality assessment products, potentially enhancing market presence in Asia-Pacific regions through humanitarian initiatives like EPICC aimed at combating cervical cancer.

TSX:MBX Revenue & Expenses Breakdown as at May 2025
TSX:MBX Revenue & Expenses Breakdown as at May 2025

NamSys

Simply Wall St Financial Health Rating: ★★★★★★